摘要
目的 :评价国产卡维地洛与拉贝洛尔的降压疗效。方法 :轻、中度高血压病病人 2 0 0例 ,采用平行、随机、双盲对照方法 ,其中卡维地洛组 10 0例 ,给卡维地洛 10～ 2 0mg ,po ,bid ;拉贝洛尔组 10 0例给拉贝洛尔 50～ 10 0mg ,po ,bid ;对另 2 0例开放服卡维地洛 ,4 0mg ,po ,qd ;2药均服 4wk。结果 :2药均能明显降压、减慢心率 ;总有效率卡维地洛为 83% ,拉贝洛尔为 75% ,组间比较 (P >0 .0 5)。对 2 0例开放服卡维地洛者 ,治疗前后经 2 4h动态血压监测 ,发现日间平均血压下降及心率减慢差别均有显著意义 (P <0 .0 5或P <0 .0 1) ;对 2 0例中的10例计算血压谷 /峰比值 :SBP为 58% ,DBP为36 %。结论 :2药治疗轻、中度高血压病疗效均较好而安全。
AIM: To evaluate the efficacy and safety of carvedilol in treating essential hypertension. METHODS: Two hundred patients with mild to moderate essential hypertension(M 120,F 80,age 53 a± s 9 a) were studied. They received carvedilol ( n =100) and labetalol ( n =100) in a double blind randomized, parallel design. The doses of carvedilol 10～20 mg, po ,bid×4 wk and labetalol 50～100 mg, po ,bid×4 wk. respectively. Another 20 patients received carvedilol 40 mg, po ,qd in open trail who did 24 h ambulatory blood pressure monitoring(ABPM) before and after 4 wk treatment. RESULTS: The blood pressure and heart rate were gradually decreasing since 1 wk after receiving both carvedilol and labetalol, and the total response rates (defined as a decrease in sitting DBP to ≤12 kPa or by ≥1.33 kPa from baseline) were 83 % and 75 % respectively ( P >0.05) at the end of 4 wk. 24 h ABPM showed significantly mean blood pressure reduction after 4 wk treatment of carvedilol 40 mg, po , qd and T/P ratio: SBP 58 %, DBP 36 %. CONCLUSION: Carvedilol is effective, safe and similar to that of labetalol in treating mild to moderate essential hypertension.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2000年第3期181-184,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
卡维地洛
拉贝洛尔
高血压
动态血压
药物疗法
carvedilol
labetalol
hypertension
ambulatory blood pressure monitoring
